Core Viewpoint - Saint Noble Pharmaceuticals-B (02257) has seen a significant increase in its stock price, with a year-to-date rise exceeding 530% as of the latest report [1] Group 1: Stock Performance - The stock price of Saint Noble Pharmaceuticals rose by over 9%, currently trading at 22.06 HKD with a trading volume of 29.72 million HKD [1] - The cumulative increase in stock price for the year has surpassed 530% [1] Group 2: Investment and Strategic Partnership - Saint Noble Pharmaceuticals announced a placement of 17.35 million new shares at a discount of 19.84% to four investors, including Huaxi Biotechnology (Hong Kong) [1] - Huaxi Biotechnology plans to invest approximately 138 million CNY through its wholly-owned subsidiary, acquiring about 9.44% of Saint Noble Pharmaceuticals post-placement [1] - The investment aims to advance research and commercialization in medical aesthetics, aging intervention, and regenerative medicine, particularly focusing on the STP705 targeted fat reduction project and other siRNA-based medical aesthetic assets [1] - Huaxi Biotechnology emphasizes its role as a strategic investor, indicating potential for further business collaboration with Saint Noble Pharmaceuticals [1]

Core Viewpoint - Huaxi Biological has made a strategic investment in Saint No Pharmaceutical, focusing on the potential of small nucleic acid and RNAi technology in the medical aesthetics sector, particularly in targeted fat reduction [1][2][3]. Investment Details - On September 8, Saint No Pharmaceutical announced a share placement of 17.35 million new shares at HKD 12 per share, with Huaxi Hong Kong, a wholly-owned subsidiary of Huaxi Biological, investing HKD 138 million for 11.57 million shares [1][2]. - The share placement represents approximately 16.50% of the existing issued share capital and 14.16% of the enlarged share capital of Saint No Pharmaceutical [2]. - The placement price reflects a discount of about 19.84% compared to the closing price of HKD 14.97 on September 5 [2]. Company Performance - Huaxi Biological recently reported its worst half-year results since its listing, with revenue and net profit declining by 19.57% and 33.97% year-on-year, respectively [1][5]. - The company's three main business segments—skin science innovation, medical terminal products, and raw materials—experienced varying degrees of decline [5]. - The skin science innovation segment, which is the main revenue driver, saw a significant drop in revenue, contributing only 40.36% to total revenue in the first half of 2025 [5]. Strategic Rationale - The investment in Saint No Pharmaceutical is seen as a proactive strategy to explore new growth opportunities amid declining performance [6][8]. - Huaxi Biological aims to leverage Saint No's research capabilities in RNAi technology to enhance its own product offerings in medical aesthetics and regenerative medicine [3][6]. - The collaboration is expected to facilitate clinical development and commercialization of targeted fat reduction projects in the Greater China region [3]. Historical Context - Huaxi Biological has a history of investments in the pharmaceutical sector, previously acting as a limited partner in various private equity funds [7][8]. - The company has also engaged in acquisitions to expand its capital footprint, including the purchase of a hyaluronic acid raw material supplier and a collagen production company [8][9]. - The founder, Zhao Yan, has a strong background in investment, which may influence the company's strategic direction [9][10].

Group 1 - Sanofi Pharmaceutical announced a subscription agreement with four investors, including Huaxi Biotechnology (Hong Kong) Co., Ltd., to issue 17.3524 million new shares at HKD 12 per share, raising approximately HKD 208.2 million, which accounts for 14.16% of the enlarged share capital [1] - Following the announcement, Sanofi Pharmaceutical's stock price surged nearly 23% on the day of the announcement and continued to rise by nearly 7% the next day, reaching HKD 19.65 per share [2] - Huaxi Biotechnology's strategic investment in Sanofi Pharmaceutical is driven by optimism regarding the development prospects of small nucleic acid drugs and RNAi technology, which have expanded applications in metabolic diseases, tumors, and medical aesthetics [2] Group 2 - Sanofi Pharmaceutical focuses on new drug development centered around RNA interference technology, possessing proprietary delivery platforms such as GalNAc and PNP, with the PNP platform being the first in Asia to achieve targeted delivery of small nucleic acids to non-liver tissues [3] - The core RNAi therapy product STP705 has completed Phase I clinical research for targeted fat reduction in the U.S. and is the first drug to achieve 100% complete clearance in Phase II trials for skin basal cell carcinoma patients [3] - Despite these advancements, Sanofi Pharmaceutical has not yet achieved profitability, reporting a loss of HKD 3.698 million in the first half of 2025 and an expected annual loss of HKD 51.38 million for 2024 [3] Group 3 - Huaxi Biotechnology is undergoing a transformation due to industry conditions and cyclical factors, with its main revenue source, skin science innovation, declining significantly [4] - The company's revenue dropped from HKD 6.359 billion in 2022 to HKD 5.371 billion in 2024, and net profit fell from HKD 971 million to HKD 174 million [4] - In the first half of this year, Huaxi Biotechnology's revenue decreased by 19.57% year-on-year to HKD 2.261 billion, with income from skin science innovation down by 33.97% to HKD 912 million [4]

据悉，此项投资旨在大幅推进圣诺医药在医学美容、衰老干预及再生医学领域的研发与商业化进程。华 熙生物将特别针对STP705靶向减脂项目及其他基于siRNA的医学美容管线资产投入大量资源，包括大中 华地区及全球的临床研发专业知识与商业化能力。 圣诺医药-B(02257)再涨超12%，月内累计涨幅已超120%。截至发稿，涨11.32%，报20.46港元，成交额 1705.02万港元。 消息面上，圣诺医药早前宣布，向华熙生物科技(香港)等四名投资者折让19.84%配售合共1,735.24万股 新股份。华熙生物(688363.SH)表示，此次通过旗下全资子公司斥资约1.38亿元，认购圣诺医药战略配售 的股份，完成配售后公司将持股圣诺医药约9.44%，未来不单是财务投资人，更是战略投资者，双方将 探讨更多业务层面合作的可能性，体现双方的长期战略协同。 ...

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Saint Noble Pharmaceuticals-B (02257), which has risen over 120% within the month, with a current price of 20.46 HKD and a trading volume of 17.05 million HKD [1] - Saint Noble Pharmaceuticals announced a placement of 17.35 million new shares at a discount of 19.84% to four investors, including Huaxi Biotechnology (Hong Kong) [1] - Huaxi Biotechnology plans to invest approximately 138 million CNY through its wholly-owned subsidiary to acquire shares in Saint Noble Pharmaceuticals, resulting in a 9.44% ownership stake, indicating a shift from being merely a financial investor to a strategic partner [1] Group 2 - The investment aims to significantly advance Saint Noble Pharmaceuticals' research and commercialization efforts in the fields of medical aesthetics, aging intervention, and regenerative medicine [1] - Huaxi Biotechnology will allocate substantial resources towards the STP705 targeted fat reduction project and other siRNA-based medical aesthetic pipeline assets, leveraging clinical research expertise and commercialization capabilities in Greater China and globally [1]

Core Viewpoint - The strategic investment by Huaxi Biological in Shengnuo Pharmaceutical, known as "China's first nucleic acid drug stock," has significantly impacted the latter's stock price, which surged by 34.41% to HKD 4.57 per share as of September 8 [2]. Group 1: Investment Details - Shengnuo Pharmaceutical announced a discounted share placement of approximately 20%, aiming to raise HKD 208 million by issuing 17.35 million new shares at HKD 12 per share, which represents about 16.50% of the existing share capital [3][6]. - The investors in this placement include Huaxi Biological Technology (Hong Kong) Co., Ltd., and three other investors, with Huaxi Biological acquiring shares worth HKD 138 million, resulting in a 9.44% ownership stake [5][6]. Group 2: Financial Performance - Shengnuo Pharmaceutical has been in a loss-making state since its listing in 2021, with no product sales revenue generated as of June 30 this year [7]. - The company reported a total revenue of HKD 0.01 million for the first half of 2025, a decrease of 87.40% year-on-year, while total expenses were HKD 0.44 million, leading to an operating loss of HKD 0.43 million [8]. Group 3: Market Context - Huaxi Biological's investment is seen as a move to diversify its growth avenues beyond the beauty industry, especially as the company reported a 19.57% decline in revenue to HKD 2.26 billion and a 35.38% drop in net profit to HKD 221 million for the first half of 2025 [10][11]. - The company is also undergoing significant management changes and reforms to revitalize its operations, with 11 senior executives leaving the company recently [11].

Core Viewpoint - Huaxi Biological's strategic investment in Shengnuo Pharmaceutical, known as "China's first nucleic acid drug stock," has significantly impacted the stock price, which surged by 34.41% to HKD 4.57 per share as of September 8 [1] Group 1: Investment Details - Shengnuo Pharmaceutical announced a nearly 20% discounted share placement to raise HKD 208 million, with Huaxi Biological being a notable subscriber [2][4] - The share placement involves issuing 17.35 million new shares at HKD 12 per share, representing approximately 16.50% of the existing share capital [4][6] - Huaxi Biological, through its wholly-owned subsidiary, subscribed for HKD 138 million worth of shares, acquiring a 9.44% stake in Shengnuo [6] Group 2: Company Performance - Shengnuo Pharmaceutical has been in a loss-making state since its listing in 2021, with no product sales revenue generated as of June 30 this year [3][8] - The company focuses on RNA interference (RNAi) technology for new drug development, with its main candidate, STP705, currently in clinical development for two cancer indications [9] - Shengnuo's financials show total revenue of HKD 0.01 million for the first half of 2025, a decrease of 87.40% year-on-year, with total expenses of HKD 440 million [9] Group 3: Huaxi Biological's Performance - Huaxi Biological's performance has been under pressure, with a 19.57% decline in revenue to HKD 2.26 billion for the first half of 2025, and a 35.38% drop in net profit to HKD 220 million [11][12] - The company's largest revenue segment, skin science innovation, saw a 33.97% decrease in revenue to HKD 912 million [11] - The founder of Huaxi Biological has returned to implement reforms, including a strict anti-corruption policy and management restructuring [12]

Group 1 - The medical beauty sector increased by 4.3% on September 8, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 3826.84, up 0.38%, while the Shenzhen Component Index closed at 12666.84, up 0.61% [1] - Huaxi Biological's stock price rose by 5.01% to 60.00, with a trading volume of 105,400 shares and a transaction value of 636 million [1] Group 2 - The medical beauty sector saw a net inflow of 60.43 million in main funds, while retail investors contributed a net inflow of 16.59 million [1] - Aimei Ke's stock experienced a net outflow of 65.20 million, with a decline of 4.12% [2] - ST Meigu's stock had a significant net outflow of 11.19 million, reflecting a decrease of 40.89% [2]

华熙生物通过旗下全资子公司认购港股上市公司圣诺医药战略配售的股份，认购价格为12元港币，认购 金额约为1.38亿港元，配售完成后，其将持有圣诺医药约9.44%的总股本。 ...

Core Viewpoint - Sainteno Pharmaceuticals-B (02257) has seen its stock price increase by over 90% in the month, with a current rise of 18.84% to HKD 17.79, and a trading volume of HKD 45.3042 million [1] Group 1: Fundraising and Stock Performance - Sainteno Pharmaceuticals announced a plan to issue 17.3524 million subscription shares to Huaxi Biotechnology (Hong Kong) Co., Ltd. and two other parties at HKD 12.00 per share, representing a discount of approximately 19.84% compared to the closing price of HKD 14.97 on September 5 [1] - The fundraising is expected to net approximately HKD 206 million, which will be used for general operating funds [1] Group 2: Product Development and Clinical Trials - STP705 is the fastest progressing product in Sainteno's pipeline, anticipated to become the company's first commercialized product by 2025 [1] - STP705 targets both TGF-β1 and COX-2 as a dual-target siRNA and is the first and only drug in the siRNA cancer treatment field to achieve positive Phase II clinical results [1] - In the Phase II clinical trial for treating basal cell carcinoma, the 180ug dosage group achieved a 100% complete clearance rate [1] - The company is expanding STP705's indications, having initiated Phase II clinical trials for scars, Phase I clinical trials for adult abdominal liposuction, and Phase I clinical trials for liver cancer [1] - STP705 has also received orphan drug designation for the treatment of cholangiocarcinoma and primary sclerosing cholangitis [1]